EAN 2026 | Guidance for clinicians on the real-world use of foslevodopa/foscarbidopa for PD

K. Ray Chaudhuri, MD, DSc, FRCP, FEAN, King’s College London, London, United Kingdom, comments on the benefits and challenges of foslevodopa/foscarbidopa infusion for the treatment of Parkinson’s disease (PD). Prof. Chaudhuri highlights its advantages in providing continuous dopaminergic stimulation and addressing nighttime issues, but notes that clinicians should be aware of potential risks including skin reactions and psychosis. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.